A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Conditions

• Geographic Atrophy
• Macular Degeneration

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• Avacincaptad pegol (ACP) — DRUG
  intravitreal injection

Study Details

This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy. This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor have decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas). People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for around 5 years.

Key Dates

Start date

Jan 22, 2025

Status verified

Jun 2026

Primary completion

Oct 31, 2030

Completion

Oct 31, 2030

Study Design

Enrollment

500 participants (estimated)

Arms

• Arm: Izervay
  Patients with geographic atrophy (GA) secondary to AMD who have made decision to begin treatment with Izervay

Primary Outcome Measure

Number of ACP injections [ Time Frame: Up to 61 Months ]

Central Contacts

• Astellas Pharma Global Development, Inc.
  800-555-5555
  [email protected]

Locations (65)

Find similar trials in Phoenix, AZ

Related Studies

• High Resolution Retinal Imaging
  Recruiting · University of Pennsylvania · Philadelphia, Pennsylvania
• Stem Cell Ophthalmology Treatment Study II
  Recruiting · MD Stem Cells · Westport, Connecticut
• Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
  EARLY_PHASE1 · Recruiting · MediBeacon · Ann Arbor, Michigan
• Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
  PHASE1/PHASE2 · Recruiting · National Eye Institute (NEI) · Baltimore, Maryland